Efficacy and safety of GSK3923868 inhalation powder, during experimental human rhinovirus infection in participants with mild asthma

Trial Identifier:	213499
Sponsor:	GlaxoSmithKline
Collaborator:	Not applicable
Start Date:	June 2022
Primary Completion Date:	April 2024
Study Completion Date:	April 2024
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United Kingdom	London, United Kingdom, E1 2AX

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.